Abstract
p38 mitogen activated protein (MAP) kinase remains the most compelling therapeutic target for oral drug intervention for a wide range of autoimmune disorders based on the central role this enzyme plays in inflammatory cell signaling. Efforts to discover inhibitors of p38 suitable for clinical investigation have continued to escalate in part due to the incredible diversity of unique chemotypes reported to inhibit the enzyme. Since 1993, at least seventeen p38 inhibitors have been reported to have entered into clinical trials. Next generation inhibitors have been disclosed with improved potency for p38 and enhanced selectivity versus other protein kinases. Over the last three years, there have been multiple reports of cytokine suppression in humans following oral administration of p38 inhibitors. These results, in addition to proof of concept studies in rheumatoid patients, have established p38 inhibition as an avenue for the future management of pro-inflammatory cytokine based diseases. This review describes the discovery at Roche of novel p38 inhibitors which have advanced into clinical trials. The pharmacology of the Roche compounds is then compared with eight chemically distinct p38 inhibitors known to have entered clinical development.
Keywords: map kinase, tumor necrosis factor, tnf, interleukin, rheumatoid arthritis, kinase inhibitor
Current Topics in Medicinal Chemistry
Title: Pathway to the Clinic: Inhibition of P38 MAP Kinase. A Review of Ten Chemotypes Selected for Development
Volume: 5 Issue: 10
Author(s): David M. Goldstein and Tobias Gabriel
Affiliation:
Keywords: map kinase, tumor necrosis factor, tnf, interleukin, rheumatoid arthritis, kinase inhibitor
Abstract: p38 mitogen activated protein (MAP) kinase remains the most compelling therapeutic target for oral drug intervention for a wide range of autoimmune disorders based on the central role this enzyme plays in inflammatory cell signaling. Efforts to discover inhibitors of p38 suitable for clinical investigation have continued to escalate in part due to the incredible diversity of unique chemotypes reported to inhibit the enzyme. Since 1993, at least seventeen p38 inhibitors have been reported to have entered into clinical trials. Next generation inhibitors have been disclosed with improved potency for p38 and enhanced selectivity versus other protein kinases. Over the last three years, there have been multiple reports of cytokine suppression in humans following oral administration of p38 inhibitors. These results, in addition to proof of concept studies in rheumatoid patients, have established p38 inhibition as an avenue for the future management of pro-inflammatory cytokine based diseases. This review describes the discovery at Roche of novel p38 inhibitors which have advanced into clinical trials. The pharmacology of the Roche compounds is then compared with eight chemically distinct p38 inhibitors known to have entered clinical development.
Export Options
About this article
Cite this article as:
Goldstein M. David and Gabriel Tobias, Pathway to the Clinic: Inhibition of P38 MAP Kinase. A Review of Ten Chemotypes Selected for Development, Current Topics in Medicinal Chemistry 2005; 5 (10) . https://dx.doi.org/10.2174/1568026054985939
DOI https://dx.doi.org/10.2174/1568026054985939 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diadenosine Polyphosphates: Postulated Mechanisms Mediating the Cardiac Effects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Incretins and Preservation of Endothelial Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Vasopressin Antagonists as Anxiolytics and Antidepressants: Recent Developments
Recent Patents on CNS Drug Discovery (Discontinued) Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process
Current Topics in Medicinal Chemistry Pathologically-Activated Therapeutics for Neuroprotection: Mechanism of NMDA Receptor Block by Memantine and S-Nitrosylation
Current Drug Targets Assessing Systemic Arterial Hypertension Through Echocardiography: A Review for the Clinician
Current Hypertension Reviews Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection
Current Drug Metabolism Drug Delivery Systems for the Treatment of Diabetes Mellitus: State of the Art
Current Pharmaceutical Design Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Modulation of Stem Cell Differentiation by the Influence of Nanobiomaterials/ Carriers
Current Stem Cell Research & Therapy Phage-Displayed Combinatorial Peptide Libraries in Fusion to β-Lactamase as Reporter for an Accelerated Clone Screening: Potential Uses of Selected Enzyme-Linked Affinity Reagents in Downstream Applications
Combinatorial Chemistry & High Throughput Screening Biomedical Application of Polymers: A Case Study of Non-CNS Drugs Becoming CNS Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Effects of Novel Alkyl Pyridine Platinum Complexes on Apoptosis in Ishikawa Endometrial Cancer Cells
Medicinal Chemistry Chelating Agents for Metal Intoxication
Current Medicinal Chemistry The Smart Targeting of Nanoparticles
Current Pharmaceutical Design Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Brain Perfusion In Sepsis
Current Vascular Pharmacology Anti-Inflammatory and Antioxidant Effects of Resveratrol in Healthy Smokers A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial
Current Medicinal Chemistry 3D MI-DRAGON: New Model for the Reconstruction of US FDA Drug- Target Network and Theoretical-Experimental Studies of Inhibitors of Rasagiline Derivatives for AChE
Current Topics in Medicinal Chemistry